Details of investments in which the company holds 20% or more of the nominal value of any class of share capital are as follows:
Subsidiary undertakings
ArgantriX Limited - Ordinary £0.01 shares - 50.2% holding (2023: 50.2%)
EstryX Pharma Limited - Ordinary £0.01 shares - 50.0% holding (2023: 50.0%)
Nebuquine Limited - Ordindary £0.01 shares - 57.0% holding (2023: 57.0%)
IPgeniX Limited - Ordinary £1.00 shares - 76% holding (2023: 100.0%)
Associates
CholesteniX Limited - Ordinary £0.10 shares - 28.7% holding (2023: 28.7%)
GliaGenesis Limited - Ordinary £0.01 shres - 47.5% holding (2023: 47.5%)
The registered office address for all of the subsidiary undertakings and associates is Orchard Lea, Horns Lane, Combe, Witney, Oxfordshire, OX29 8NH and the principal activity is that of scientifc consultancy.